Shedding Light on Acquired Treatment Resistance in Lung Cancer
New research indicates that lung cancers develop resistance to gefitinib (Iressa) through MET oncogene amplification on ERBB3 signaling.
This entry was posted on Thursday, April 26th, 2007 at 7:44 pm and is filed under Research. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
